Compare COEP & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COEP | PCM |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 82.0M |
| IPO Year | N/A | N/A |
| Metric | COEP | PCM |
|---|---|---|
| Price | $11.98 | $5.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.8K | ★ 51.9K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.68% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $5.52 |
| 52 Week High | $21.41 | $6.76 |
| Indicator | COEP | PCM |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 46.59 |
| Support Level | $10.65 | $5.52 |
| Resistance Level | $13.23 | $6.15 |
| Average True Range (ATR) | 0.88 | 0.10 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 78.01 | 67.74 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.